Biological Dynamics appoints Peter Wulff, a veteran of the industry, as Chief Financial Officer
SAN DIEGO, Jan. 17, 2023 /PRNewswire/ — Biological Dynamics, Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.
Over 35 years of experience in financial management in public and private companies in the emerging growth life sciences has earned Mr. Wulff over $35 million. JenaValve Technology’s Chief Financial Officer was where he played a pivotal role in the recent corporate relocation. Germany Its subsequent expansion in the US. He also managed various capital raise transactions including equity, debt, and international out-licensing intellectual property. Peter served as the financial officer for several medical technology companies, including Alphatec Spine Holdings (Artes Medical), CryoCor and Pure Biosciences.
“Biological Dynamics is a pioneer in the emerging space for extracellular vesicles, exosome isolation and early detection of cancer. Peter, a seasoned industry veteran, joins our team as we continue to invest in our priorities to grow our commercial portfolio and to drive growth. Paul R. BillingsBiological Dynamics Director and CEO Dr. Michael D. Grainger, MD, PhD. “Exosomes enable highly sensitive cancer detection assays. They can also be used to deliver drugs and treat patients. These workflows can all be made possible by the ExoVerita platform.
“It’s an honor to join Biological Dynamics. I look forward enhancing efforts to increase adoption of our innovative and proprietary technology to detect early signs of disease,” said Mr. Peter Wulff. “The company’s historical scientific and development efforts have reached an inflection level where future investments should increase clinical utility for various diseases that could allow preventative medical intervention.”
About Biological Dynamics
Biological Dynamics, Inc., is dedicated to improving global health outcomes through early detection of diseases. The Company’s proprietary ExoVerita™ platform simplifies isolation of extracellular vesicles, enabling multiomic applications. The PDAC test is performed in a CLIA-certified, accredited clinical laboratory by the College of American Pathologists (CAP). San Diego. Biological Dynamics recently announced the initiation of the ExoLuminate™ study, a clinical trial to demonstrate effectiveness of early-stage detection of pancreatic cancer. Find out more at www.ExoLuminate.com.
Contact: Kellee Johnson, 312-751-3959, [email protected]
To view original content, you can download multimediahttps://www.prnewswire.com/news-releases/biological-dynamics-appoints-industry-veteran-peter-wulff-as-chief-financial-officer-301723505.html
SOURCE: Biological Dynamics